Changes in normalized DNA levels in samples of MG-63 cells during culture with various TSP concentrations: (a) 0 mM, (b) 1 mM, (c) 5 mM, (d) 10 mM, (e) 20 mM and (f) 30 mM.

<p>(n = 10, *: p<0.05, **: p<0.01).</p

DNA amount and cell viability as a function of TSP concentration for each culture period.

<p><b>DNA amounts at day 1 (a), day 3 (b), day 7 (c) and day 14 (d); cell-viability at day 1 (e), day 3 (f), day 7 (g) and day 14 (h).</b> All values are normalized to TSP-zero values at each time point. (* p<0.05).</p

Fluorescence microscope images of nuclear counterstains with Hoechst staining and TUNEL assay.

<p>Proliferation (blue color) and apoptosis (small green spots) of MG-63 cell samples cultured with 0, 1, 10 and 30 mM of TSP for 1, 3 and 4 days were illustrated.</p

Graphical illustration of changes in DNA levels (cell proliferation) at days 1, 3, 7 and 14 with various TSP concentrations (0, 1, 3, 4, 7, 10, 20 and 30 mM) by DNA assay (n = 10).

<p>Symbols indicate significant differences in comparison with the TSP-free (0 mM) specimen (§: p<0.02, †: p<0.01, ‡:p<0.001).</p

Graphical representation of the normalized changes in cell viability during two weeks of culture with various concentrations of the NMR reference reagent, TSP (n = 10 for each group, *: p<0.05).

<p>Graphical representation of the normalized changes in cell viability during two weeks of culture with various concentrations of the NMR reference reagent, TSP (n = 10 for each group, *: p<0.05).</p

Commonly activated regions in FM patients and healthy control.

<p>Yellow clusters indicate common regions activated by painful stimuli in FM patients and healthy controls. Common regions include bilateral cerebellum, contralateral supramarginal gyrus, IFG and MFG.</p

Statistical comparisons of clinical scores.

<p>(Mean and SD.) (A) FM patients and healthy controls (B) pre-treatment group and post-treatment group. Fibromyalgia Impact Questionnaire (FIQ), Brief Fatigue Inventory (BFI), Beck Depression Inventory (BDI), Widespread Pain Index (WPI), Symptom Severity Scale score (SSS), and State-Trait Anxiety Inventory (STAI). * <i>p</i> < 0.05, ** <i>p</i> < 0.01.</p

Outline of the study design and classification of subjects used for evaluation of the effectiveness of pregabalin in the treatment of patients with fibromyalgia, using fMRI.

<p>Outline of the study design and classification of subjects used for evaluation of the effectiveness of pregabalin in the treatment of patients with fibromyalgia, using fMRI.</p

Comparison between FM patients and healthy controls.

<p>Augmented brain activation regions in FM patients compared with healthy controls resulting from the same level of subjective pain intensity (GBS level 14). Regions are Bilateral Supramarginal gyrus, ipsilateral cerebellum, contralateral calcarine, STG, IFG, thalamus and insula.</p

Pain-stimulation paradigm of the fMRI scan.

<p>Pain-stimulation paradigm of the fMRI scan.</p